文献速递胸部肿瘤支持与姑息治疗

肺癌患者抑郁症状的纵向变化与生存:一项全国队列评估

Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment.
PubMed 文献 · J Clin Oncol · 2016-10-31

这项前瞻性观察研究纳入美国五个地区1790例肺癌患者,诊断时及12个月随访时评估抑郁症状。基线抑郁症状与死亡率升高相关(HR 1.17),纵向变化分组中新发和持续抑郁症状者死亡风险高于从未抑郁者,早期患者尤为明显,症状缓解者死亡率与从未抑郁者相似。

要点

  • 基线抑郁症状与死亡率升高相关(HR 1.17)。
  • 新发抑郁症状者死亡风险高于从未抑郁者(HR 1.50)。
  • 持续抑郁症状者死亡风险高于从未抑郁者(HR 1.42)。

核心结论

  • 肺癌患者抑郁症状的纵向变化与死亡率差异相关,尤其在早期患者中。
  • 抑郁症状缓解者的死亡率与从未患抑郁者相似。

研究设计与样本

  • 前瞻性观察研究,来自美国五个地理区域癌症照护结局研究与监测联盟,2003年9月至2005年12月。
  • 在肺癌诊断后3个月内入组,诊断时和12个月随访时使用八条目流行病学研究中心抑郁量表评估。
  • 共纳入1790例参与者,主要结局为生存,采用Kaplan-Meier曲线和校正Cox比例风险模型评估。

主要发现

  • 1790例参与者中,681例(38%)基线有抑郁症状,另105例(14%)在治疗期间出现新发抑郁症状。
  • 基线抑郁症状与死亡率升高相关(HR 1.17;95% CI 1.03至1.32;P=.01)。
  • 与从未抑郁症状组(n=640)相比,新发抑郁症状组(n=105)HR 1.50(95% CI 1.12至2.01;P=.006)。
  • 与从未抑郁症状组相比,抑郁症状缓解组(n=156)HR 1.02(95% CI 0.79至1.31;P=.89),持续抑郁症状组(n=254)HR 1.42(95% CI 1.15至1.75;P=.001)。
  • 基线时,早期疾病(I和II期)参与者中抑郁症状与死亡率升高相关(HR 1.61;95% CI 1.26至2.04),晚期疾病(III和IV期)中不相关(HR 1.05;95% CI 0.91至1.22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Depression symptoms are common among patients with lung cancer; however, longitudinal changes and their impact on survival are understudied. Methods This was a prospective, observational study from the Cancer Care Outcomes Research and Surveillance Consortium from five US geographically defined regions from September 2003 through December 2005. Patients enrolled within 3 months of their lung cancer diagnosis were eligible. The eight-item Center for Epidemiologic Studies Depression scale was administered at diagnosis and 12 months' follow-up. The main outcome was survival, which was evaluated using Kaplan-Meyer curves and adjusted Cox proportional hazards modeling. Results Among 1,790 participants, 681 (38%) had depression symptoms at baseline and an additional 105 (14%) developed new-onset depression symptoms during treatment. At baseline, depression symptoms were associated with increased mortality (hazard ratio [HR], 1.17; 95% CI, 1.03 to 1.32; P = .01). Participants were classified into the following four groups based on longitudinal changes in depression symptoms from baseline to follow-up: never depression symptoms (n = 640), new-onset depression symptoms (n = 105), depression symptom remission (n = 156), and persistent depression symptoms (n = 254) and HRs were calculated. Using the never-depression symptoms group as a reference group, HRs were as follows: new-onset depression symptoms, 1.50 (95% CI, 1.12 to 2.01; P = .006); depression symptom remission, 1.02 (95% CI, 0.79 to 1.31; P = .89), and persistent depression symptoms, 1.42 (95% CI, 1.15 to 1.75; P = .001). At baseline, depression symptoms were associated with increased mortality among participants with early-stage disease (stages I and II; HR, 1.61; 95% CI, 1.26 to 2.04), but not late-stage disease (stages III and IV; HR, 1.05; 95% CI, 0.91 to 1.22). At follow-up, depression symptoms were associated with increased mortality among participants with early-stage disease (HR, 1.71; 95% CI, 1.27 to 2.31) and those with late-stage disease (HR, 1.32; 95% CI, 1.04 to 1.69). Conclusion Among patients with lung cancer, longitudinal changes in depression symptoms are associated with differences in mortality, particularly among patients with early-stage disease. Symptom remission is associated with a similar mortality rate as never having had depression.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sullivan DR, Forsberg CW, Ganzini L, et al. Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment. J Clin Oncol. 2016. PMID: 27996350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。